Phase 3 Study Shows Burosumab is Superior than Traditional Therapies for X-Linked Hypophosphatemia (XLH)

At the 2019 annual meeting of The Endocrine Society, ENDO 2019, results from a recent study evaluating burosumab for the treatment of X-linked hypophosphatemia (XLH) were presented. This drug was…

Continue Reading Phase 3 Study Shows Burosumab is Superior than Traditional Therapies for X-Linked Hypophosphatemia (XLH)

Targeted drug for leukemia tested at Penn Medicine helps patients live longer

The oral inhibitor drug gilteritinib (XOSPATA®) was recently approved by the USFDA based on interim results of the clinical trial ADMIRAL according to an article in EurekAlert for Science News. A total of 371 adult patients…

Continue Reading Targeted drug for leukemia tested at Penn Medicine helps patients live longer
A Noninvasive Stool Test Could Identify Cirrhosis In Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
DarkoStojanovic / Pixabay

A Noninvasive Stool Test Could Identify Cirrhosis In Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis

Nonalcoholic fatty liver disease (NAFLD) is a condition in which the buildup of fat in the liver poses health concerns. Nonalcoholic Steatohepatitis (NASH) is a more severe, and more rare…

Continue Reading A Noninvasive Stool Test Could Identify Cirrhosis In Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
Close Menu